Indoco Remedies receives tentative ANDA approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets

Indoco Remedies Ltd. announced the receipt of tentative approval from the USFDA for Abbreviated New Drug Application (ANDA) for Canagliflozin and Metformin Hydrochloride Tablets, 50 mg/500 mg, 50 mg/1000 mg, 150 mg/500 mg and 150 mg/1000 mg, a generic equivalent of Invokamet® Tablets, 50 mg/500 mg, 50 mg/1000 mg, 150 mg/500 mg and 150 mg/1000 mg.

This product, Canagliflozin and Metformin Hydrochloride Tablets, will be manufactured by Indoco Remedies Limited, at their manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa - 403722 in India. Canagliflozin and Metformin Hydrochloride Tablets are used to treat type 2 diabetes mellitus.

Commenting on the achievement, Ms. Aditi Panandikar, Managing Director said, "We are excited to receive the tentative approval from the USFDA for our Canagliflozin and Metformin Hydrochloride Tablets. This milestone underscores our commitment to bringing affordable and effective treatment options to patients managing type 2 diabetes."

Shares of Indoco Remedies Limited was last trading in BSE at Rs. 315.95 as compared to the previous close of Rs. 309.25. The total number of shares traded during the day was 9475 in over 413 trades.

The stock hit an intraday high of Rs. 320.35 and intraday low of 312.95. The net turnover during the day was Rs. 2999044.00.

Source : Equity Bulls

Keywords

IndocoRemedies INE873D01024 USFDA TentativeApproval ANDA Canagliflozin MetforminHydrochloride Tablets